From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 3
Total Number 3
Disease Relevance 0.69
Pain Relevance 0.70

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Dpp4) extracellular region (Dpp4) cell adhesion (Dpp4)
Golgi apparatus (Dpp4) endoplasmic reticulum (Dpp4) plasma membrane (Dpp4)
Anatomy Link Frequency
EM-2 1
Dpp4 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
substance P 1 99.20 Very High Very High Very High
agonist 1 98.28 Very High Very High Very High
Neuropeptide 2 96.28 Very High Very High Very High
Analgesic 1 92.00 High High
Potency 1 91.20 High High
analgesia 1 83.00 Quite High
Pain 4 82.88 Quite High
opioid receptor 1 81.52 Quite High
Opioid 1 78.16 Quite High
chemokine 1 52.04 Quite High
Disease Link Frequency Relevance Heat
Diabetes Mellitus 36 88.72 High High
Stress 2 84.72 Quite High
Pain 2 79.12 Quite High
Body Weight 9 74.68 Quite High
Disease 1 31.08 Quite Low
Hyperinsulinism 1 24.72 Low Low
Insulin Resistance 6 15.40 Low Low
Obesity 5 8.00 Low Low
Weight Loss 20 5.00 Very Low Very Low Very Low
Vomiting 18 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The varying phenotypes of the F344 substrains are likely to be mediated by differential degradation of DPPIV substrates such as substance P, glucagon-like peptide (GLP)-1, enterostatin, and especially neuropeptide Y (NPY).
Protein_catabolism (degradation) of DPPIV associated with neuropeptide and substance p
1) Confidence 0.57 Published 2003 Journal Physiol. Behav. Section Abstract Doc Link 14568317 Disease Relevance 0.32 Pain Relevance 0.31
By removing two N-terminal amino acids, dipeptidyl peptidase-4 (DPP-4) rapidly inactivates GLP-1.14 The development of the GLP-1 receptor agonists offers incretin-based therapies with built-in modifications to provide resistance to DPP-4 degradation.

Protein_catabolism (degradation) of DPP-4 associated with agonist
2) Confidence 0.09 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2990388 Disease Relevance 0.36 Pain Relevance 0.05
EM-2 analogues with D-Ala or D-NMeAla were about twofold more potent than the parent peptide and were least prone to degradation by brain homogenate, dipeptydyl peptidase IV and aminopeptidase M.
Protein_catabolism (degradation) of peptidase IV in EM-2
3) Confidence 0.01 Published 2010 Journal Basic Clin. Pharmacol. Toxicol. Section Abstract Doc Link 19874287 Disease Relevance 0 Pain Relevance 0.34

General Comments

This test has worked.

Personal tools